Creative Medical Technology (NASDAQ:CELZ) Stock Rating Upgraded by Wall Street Zen

Creative Medical Technology (NASDAQ:CELZ) was upgraded by equities research analysts at Wall Street Zen to a “sell” rating in a research note issued to investors on Saturday.

CELZ has been the topic of several other reports. Roth Capital reissued a “buy” rating on shares of Creative Medical Technology in a research note on Thursday. Weiss Ratings raised shares of Creative Medical Technology from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, August 13th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold”.

Creative Medical Technology Stock Performance

Shares of CELZ opened at $1.31 on Friday. Creative Medical Technology has a 52-week low of $0.62 and a 52-week high of $6.25. The business’s 50 day moving average price is $1.20 and its two-hundred day moving average price is $1.77. The firm has a market cap of $8.63 million, a PE ratio of -0.63 and a beta of 1.95.

Creative Medical Technology (NASDAQ:CELZ) last announced its quarterly earnings data on Friday, August 7th. The company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.02). Research analysts predict that Creative Medical Technology will post -1.18 EPS for the current fiscal year.

Institutional Trading of Creative Medical Technology

Several institutional investors and hedge funds have recently modified their holdings of the stock. Clear Harbor Asset Management LLC bought a new stake in Creative Medical Technology during the second quarter worth $192,000. Jane Street Group LLC purchased a new stake in Creative Medical Technology in the 4th quarter valued at $59,000. Finally, Seros Financial LLC purchased a new stake in Creative Medical Technology in the 2nd quarter valued at $53,000. 1.42% of the stock is owned by hedge funds and other institutional investors.

Creative Medical Technology Company Profile

Creative Medical Technology Holdings, Inc (NASDAQ: CELZ) is a clinical‐stage biotechnology company focused on the development, manufacture and commercialization of exosome‐based therapies derived from human bone marrow mesenchymal stem cells. The company’s proprietary exosome platform is being investigated for applications in regenerative medicine, aesthetic dermatology, wound healing and anti‐inflammatory treatments. Creative Medical leverages cGMP manufacturing processes to produce sterile, cell‐free exosome formulations designed to support tissue repair and cellular rejuvenation.

The company’s lead product candidates include XoFlo, an exosome enrichment product intended for use in musculoskeletal and soft tissue injuries, and specialized formulations targeting skin rejuvenation and scar reduction.